Significant milestone reached in advancing a driverless total artificial heart, strengthening Picard Medicals leadership in total artificial heart technologyTUCSON, Ariz., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it has successfully completed the first in vivo implantations of the fully ...

Core Viewpoint - Picard Medical, Inc. will showcase its SynCardia Total Artificial Heart (STAH) at the American Heart Association (AHA) annual meeting, highlighting its status as the most widely used and studied artificial heart globally [1][5]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona. It is the leader in commercially available total artificial heart technology for patients with end-stage heart failure [5]. - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada [5]. - Over 2,100 implants of the STAH have been performed in hospitals across 27 countries, establishing it as the most widely used and extensively studied artificial heart in the world [5]. Event Participation - The AHA annual meeting will take place from November 7 to 10 in New Orleans, Louisiana, where Picard Medical will exhibit at booth 3408 [1]. - The CEO of Picard Medical expressed excitement about sharing the latest developments regarding the STAH and engaging with physicians and attendees about patient eligibility and clinical data [2]. AHA Overview - The American Heart Association (AHA) is the oldest and largest voluntary organization in the U.S. dedicated to combating heart disease and stroke, with over 35 million volunteers and supporters [4]. - The AHA has invested more than $6 billion in cardiovascular research, making it the largest non-profit funding source for cardiovascular and cerebrovascular disease research after the federal government [4].

Core Insights - Picard Medical, Inc. has strengthened its intellectual property portfolio with the grant of U.S. Patent No. 12,383,722 B2 for its next-generation SynCardia Total Artificial Heart (STAH), named "Emperor" [1][2] - The company now holds a total of 34 patented claims in the U.S. related to its next-generation total artificial heart system, with additional protection in China [1][2] - The Emperor is designed to be fully implantable and provide pulsatile flow without the need for an external pneumatic driver [1] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona, and is the leader in commercially available total artificial heart technology for patients with end-stage heart failure [4] - The SynCardia Total Artificial Heart is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the U.S. and Canada [4] - Over 2,100 implants have been performed at hospitals across 27 countries, making the SynCardia Total Artificial Heart the most widely used and extensively studied artificial heart globally [4] Strategic Goals - The company aims to expand its patent portfolio globally to protect its innovative technologies, including durable mechanisms, advanced electronics, and wireless implantable features [2][3] - The patent portfolio is seen as a foundation for the company's future, securing the path from development to commercialization and ensuring long-term global leadership in heart replacement technology [3]